Antimalarial drug discovery: Efficacy models for compound screening

被引:597
作者
Fidock, DA
Rosenthal, PJ
Croft, SL
Brun, R
Nwaka, S
机构
[1] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[3] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England
[4] Swiss Trop Inst, Dept Med Parasitol & Infect Biol, CH-4002 Basel, Switzerland
[5] Med Malaria Venture, CH-1215 Geneva 15, Switzerland
关键词
D O I
10.1038/nrd1416
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Increased efforts in antimalarial drug discovery are urgently needed. The goal must be to develop safe and affordable new drugs to counter the spread of malaria parasites that are resistant to existing agents. Drug efficacy, pharmacology and toxicity are important parameters in the selection of compounds for development, yet little attempt has been made to review and standardize antimalarial drug-efficacy screens. Here, we suggest different in vitro and in vivo screens for antimalarial drug discovery and recommend a streamlined process for evaluating new compounds on the path from drug discovery to development.
引用
收藏
页码:509 / 520
页数:12
相关论文
共 108 条
[11]   INTERACTIONS OF ATOVAQUONE WITH OTHER ANTIMALARIAL-DRUGS AGAINST PLASMODIUM-FALCIPARUM IN-VITRO [J].
CANFIELD, CJ ;
PUDNEY, M ;
GUTTERIDGE, WE .
EXPERIMENTAL PARASITOLOGY, 1995, 80 (03) :373-381
[12]   Protein farnesyltransferase and protein prenylation in Plasmodium falciparum [J].
Chakrabarti, D ;
Da Silva, T ;
Barger, J ;
Paquette, S ;
Patel, H ;
Patterson, S ;
Allen, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (44) :42066-42073
[13]   THE EFFECT OF COMBINATIONS OF QINGHAOSU (ARTEMISININ) WITH STANDARD ANTIMALARIAL-DRUGS IN THE SUPPRESSIVE TREATMENT OF MALARIA IN MICE [J].
CHAWIRA, AN ;
WARHURST, DC ;
ROBINSON, BL ;
PETERS, W .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1987, 81 (04) :554-558
[14]   COMPARISON OF INVITRO AND INVIVO ANTIMALARIAL ACTIVITIES OF 9-PHENANTHRENECARBINOLS [J].
CHILDS, GE ;
LAMBROS, C ;
NOTSCH, JD ;
PAMPLIN, CL ;
DAVIDSON, DE ;
AGER, A .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1984, 78 (01) :13-20
[15]  
Clough B, 2001, INFEC DIS S, P265
[16]   Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress [J].
Crabb, BS ;
Cooke, BM ;
Reeder, JC ;
Waller, RF ;
Caruana, SR ;
Davern, KM ;
Wickham, ME ;
Brown, GV ;
Coppel, RL ;
Cowman, AF .
CELL, 1997, 89 (02) :287-296
[17]   A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline [J].
Davioud-Charvet, E ;
Delarue, S ;
Biot, C ;
Schwöbel, B ;
Boehme, CC ;
Müssigbrodt, A ;
Maes, L ;
Sergheraert, C ;
Grellier, P ;
Schirmer, RH ;
Becker, K .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (24) :4268-4276
[18]   Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines [J].
De, DYD ;
Krogstad, FM ;
Byers, LD ;
Krogstad, DJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) :4918-4926
[19]   Profiling drug-like properties in discovery research [J].
Di, L ;
Kerns, EH .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2003, 7 (03) :402-408
[20]   Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria [J].
Dorsey, G ;
Vlahos, J ;
Kamya, MR ;
Staedke, SG ;
Rosenthal, PJ .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (08) :1231-1238